AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 3,RANDOMIZED, DOUBLE-BLIND, 3-ARM STUDY TO INVESTIGATE IBUZATRELVIR INADULTS WITH SYMPTOMATIC COVID-19 WHO ARE SEVERELYIMMUNOCOMPROMISED

• Protocol code: C5091018
• EudraCT code: No aplica
• Research group: Infectious Diseases
• Service: Infectious
• Principal investigator:  Len Abad, Oscar
• Pathology: Certes malalties infeccioses i parasitàries
• Phase: Fase III

A phase 2/3, multicenter, randomized, double-blind, placebo-controlled, combined dose finding and cardiovascular outcome study to investigate the efficacy and safety of CSL300 (clazakizumab) in subjects with end stage kidney disease undergoing dialysis.

• Protocol code: CSL300_2301
• EudraCT code: No aplica
• Research group: Nephrology and kidney transplantation
• Service: Nephrology
• Principal investigator:  Ramos Terrades, Natalia
• Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
• Phase: Fase III

Estudio de fase 3, aleatorizado, doble ciego, controlado conplacebo y multicéntrico para investigar la eficacia, la seguridad y la tolerabilidad deLP352 en el tratamiento de las crisis convulsivas en niños y adultos con encefalopatíasepilépticas y del desarrollo

• Protocol code: LP352-301
• EudraCT code: No aplica
• Research group: Research Group on Status Epilepticus and Acute Seizures
• Service: Neurology
• Principal investigator:  Toledo Argany, Manuel
• Pathology: Malalties del sistema nerviós
• Phase: Fase III

A randomized controlled study to assess the efficacy of topical Sinecathechins used as adjuvant therapy to topical ablative trichloroacetic acid in the Treatment of anal High grade squamous intraepithelial lesion.

• Protocol code: SINECHSIL
• EudraCT code: _
• Research group: Infectious Diseases
• Service: Infectious
• Principal investigator:  Burgos Cibrian, Joaquin
• Pathology: Certes malalties infeccioses i parasitàries
• Phase: Fase I

18-month double-blind, randomized, placebo-controlled, multicenter, Phase 3 study to evaluate the safety and efficacy of oral nizubaglustat (AZ-3102) in late-infantile and juvenile forms of Niemann-Pick type C disease and in late-infantile and juvenile-onset forms of GM1 gangliosidosis or GM2 gangliosidosis.

• Protocol code: AZA-001-301
• EudraCT code: No aplica
• Research group: Pediatric Neurology
• Service: General Pediatrics and Specialties
• Principal investigator:  Del Toro Riera, Mireia
• Pathology: Malalties del sistema nerviós
• Phase: Fase III